Dutch biotechnology company Crucell N.V. said Friday it received $230 million in contracts from supranational organizations for its Quinvaxem and Hepavax-Gene pediatric vaccines.

The company did not name the organizations. A supranational organization often involves a group of nations, with one example being the European Union.

Quinvaxem, codeveloped with Novartis, protects against several childhood diseases including diphtheria, tetanus, whooping cough, hepatitis B, and a type of influenza. Hepavax-Gene protects against hepatitis B. The contracts cover the next three years.

American depository shares of Crucell rose 26 cents to $24.40 on the Nasdaq in morning trading.